Summer research studentships, sponsored by the BC Cancer Foundation, support senior undergraduate university students and/or junior medical or dental students seeking hands-on training in cancer research in British Columbia. These studentships may address any discipline of cancer research including clinical, translational, basic, behavioral and population health.
Congratulations to this year’s recipients and their supervisors!
Read the Canadian Cancer Trials Group story on results from a pre-planned secondary analysis of the PR21 PLUDO trial.
Three BC Cancer clinical investigators are participating in the Canadian Cancer Trials Group (CCTG) VISION – Investigator Leadership Training Program, a new education and mentorship initiative focused on developing leadership skills among current and emerging clinical trialists.
Drs. Leah Lambert, Jonathan Loree and Lucia Nappi are part of the inaugural VISION cohort.
BC Cancer’s Molecular Imaging and Therapeutics Program has been recognized with the Canadian Nuclear Isotope Council (CNIC) Award for Academic Leadership — a national honour celebrating the team’s visionary leadership and impact.
At the April CNIC Annual Awards Reception at the National Arts Centre in Ottawa, Dr. François Bénard, senior executive director, Research, BC Cancer accepted the award on behalf the team, including Dr. Joseph Lau, Dr. Carlos Uribe, Dr. Arman Rahmim, Dr. Kuo-Shyan Lin, Dr. Don Wilson and many others.
Researchers at BC Cancer Research Institute (BCCRI) and UBC Chemistry have created a new way to build radioactive DNA molecules that could help reimagine how radiolabeled drugs are built. Using enzymes that normally copy genetic material, scientists programmed synthetic DNA to carry cancer‑fighting isotopes in precise patterns, opening the door to developing drugs that could both image tumors and destroy them with the same molecule.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.